Dr. Joseph Frank Pizzolato, MD

Dr. Pizzolato practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Pizzolato's NPI, 1447248109, was assigned on October 7, 2005. Dr. Pizzolato graduated from Icahn School Of Medicine At Mount Sinai in 1998. Dr. Pizzolato holds Florida license ME90372.

Dr. Pizzolato's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Pizzolato's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Pizzolato to 1 more hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pizzolato practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Pizzolato's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Pizzolato is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Pizzolato's licenses on file in 3 states: Florida, New York and New Jersey.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Pizzolato treats.

CMS data shows 1,700 Medicare services from Dr. Pizzolato across 4 procedure codes in 2024, for 209 Medicare patients. Medicare paid $89,469 for them.

CMS counts 209 Medicare patients who saw Dr. Pizzolato in 2024. The largest group is 75 to 84, with 88 patients. 71% of them have high cholesterol, and 69% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pizzolato's median patient age at 71, with 38% women.

In 2024, Dr. Pizzolato wrote 1,021 Medicare Part D claims for 155 patients. 77% of them were for generic drugs. CMS names the drug for 784 of them, across 29 drugs with 11 or more claims each, at $1,744,777 in total drug cost. In 2023, CMS named 1,064 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Pizzolato for performance year 2024, reported as part of a group. Dr. Pizzolato accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pizzolato as offering telehealth.

Dmand AI links 5 papers to Dr. Pizzolato in 2021. The most frequent topics are Antineoplastic Agents, Phytogenic, Camptothecin and Carcinoma, Non-Small-Cell Lung. Dr. Pizzolato's most frequent co-authors are Ibrahim I. Abdalla, MD, Jaffer A. Ajani, MD and Christopher H. Crane, MD.

Dmand AI links Dr. Pizzolato to 2 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Colonic Neoplasms and Rectal Diseases.

CMS Open Payments shows 1,450 general payments to Dr. Pizzolato from 63 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 67% of the total. Genentech, Inc. paid the most, $49,392.

Dmand AI lists 2 awards for Dr. Pizzolato, most recently Regional Top Doctor in 2014.

Dr. Pizzolato graduated from Icahn School Of Medicine At Mount Sinai in 1998. Dr. Pizzolato is a member of ACP.

Dr. Pizzolato is in network with 11 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.